Abstract 124: Validation of humanized TL1A mice for advancing preclinical research

Abstract TL1A, or Tumor Necrosis Factor-Like Ligand 1A, plays a pivotal role in regulating the immune system and has garnered considerable attention in the field of cancer research. Studies have shown that TL1A can impact the tumor microenvironment via inflammatory signaling, immunosuppression, and tumor growth and survival. Targeting TL1A or its downstream effects could offer new avenues for cancer treatment and immunotherapy. To this end, we generated a human TL1A knock-in (B-hTL1A) mouse model. Human TL1A gene expression in B-hTL1A mice was confirmed by RT-PCR. TL1A protein expression was not altered following TL1A humanization in B-hTL1A mice as shown by flow cytometry. Lastly, soluble human TL1A was detected in B-hTL1A mice by ELISA. Due to the purported role of TL1A in mucosal immunity, efforts to induce inflammatory bowel disease in this humanized model are currently underway. Taken together, we established a preclinical B-hTL1A mouse model for the evaluation of TL1A-targeted immunotherapy. Citation Format: Chong Li, Shujin Zhang, Zhi Zhang, Jia Feng, James Jin, Yibo Du. Validation of humanized TL1A mice for advancing preclinical research abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 124.